PSC
NKTR icon

Prentiss Smith & Co’s Nektar Therapeutics NKTR Stock Holding History

Prentiss Smith & Co’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-17
Closed -$15K – 169
2018
Q3 		$15K Hold
17
– – 0.01% 182
2018
Q2 		$12K Hold
17
– – 0.01% 196
2018
Q1 		$27K Buy
+17
New +$21.9K 0.01% 163

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prentiss Smith & Co's NKTR Position: Q4 2018 in Review

Prentiss Smith & Co sold out of Nektar Therapeutics (NKTR) in Q4 2018, closing a stake of 17 shares — an estimated $15K sold.

Prentiss Smith & Co first reported a position in NKTR in Q1 2018 and held it in 3 quarters. The position peaked at $27K in Q1 2018. 343 funds tracked by Wall St. Rank hold NKTR as of Q4 2018.

  • Prentiss Smith & Co reported no remaining Nektar Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Prentiss Smith & Co sold 17 Nektar Therapeutics shares in Q4 2018, an estimated $15K.
  • Prentiss Smith & Co first reported a position in Nektar Therapeutics in Q1 2018 and held it in 3 quarters.
  • Prentiss Smith & Co's Nektar Therapeutics position peaked at $27K in Q1 2018.
  • 343 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2018.

Based on Prentiss Smith & Co's 13F filing for Q4 2018, filed 15 Jan 2019.